Leung K W, Cheung L W T, Pon Y L, Wong R N S, Mak N K, Fan T-P D, Au S C L, Tombran-Tink J, Wong A S T
Department of Biology, Hong Kong Baptist University, Kowloon Tong, Hong Kong, China.
Br J Pharmacol. 2007 Sep;152(2):207-15. doi: 10.1038/sj.bjp.0707359. Epub 2007 Jul 2.
Angiogenesis is a crucial step in tumour growth and metastasis. Ginsenoside-Rb1 (Rb1), the major active constituent of ginseng, potently inhibits angiogenesis in vivo and in vitro. However, the underlying mechanism remains unknown. We hypothesized that the potent anti-angiogenic protein, pigment epithelium-derived factor (PEDF), is involved in regulating the anti-angiogenic effects of Rb1.
Rb1-induced PEDF was determined by real-time PCR and western blot analysis. The anti-angiogenic effects of Rb1 were demonstrated using endothelial cell tube formation assay. Competitive ligand-binding and reporter gene assays were employed to indicate the interaction between Rb1 and the oestrogen receptor (ER).
Rb1 significantly increased the transcription, protein expression and secretion of PEDF. Targeted inhibition of PEDF completely prevented Rb1-induced inhibition of endothelial tube formation, suggesting that the anti-angiogenic effect of Rb1 was PEDF specific. Interestingly, the activation of PEDF occurred via a genomic pathway of ERbeta. Competitive ligand-binding assays indicated that Rb1 is a specific agonist of ERbeta, but not ERalpha. Rb1 effectively recruited transcriptional activators and activated an oestrogen-responsive reporter gene. Furthermore, Rb1-mediated PEDF activation and the subsequent inhibition of tube formation were blocked by the ER antagonist ICI 182,780 or transfection of ERbeta siRNA, indicating ERbeta dependence.
Here we show for the first time that the Rb1 suppressed the formation of endothelial tube-like structures through modulation of PEDF via ERbeta. These findings demonstrate a novel mechanism of the action of this ginsenoside that may have value in anti-cancer and anti-angiogenesis therapy.
血管生成是肿瘤生长和转移的关键步骤。人参皂苷-Rb1(Rb1)是人参的主要活性成分,在体内和体外均能有效抑制血管生成。然而,其潜在机制尚不清楚。我们推测,强效抗血管生成蛋白色素上皮衍生因子(PEDF)参与调节Rb1的抗血管生成作用。
通过实时PCR和蛋白质印迹分析确定Rb1诱导的PEDF。使用内皮细胞管形成试验证明Rb1的抗血管生成作用。采用竞争性配体结合和报告基因试验来表明Rb1与雌激素受体(ER)之间的相互作用。
Rb1显著增加PEDF的转录、蛋白表达和分泌。对PEDF的靶向抑制完全阻止了Rb1诱导的内皮管形成抑制,表明Rb1的抗血管生成作用具有PEDF特异性。有趣的是,PEDF的激活通过雌激素受体β(ERβ)的基因组途径发生。竞争性配体结合试验表明Rb1是ERβ的特异性激动剂,而非ERα的。Rb1有效募集转录激活因子并激活雌激素反应性报告基因。此外,ER拮抗剂ICI 182,780或ERβ小干扰RNA转染可阻断Rb1介导的PEDF激活及随后的管形成抑制,表明其对ERβ的依赖性。
我们首次表明,Rb1通过ERβ调节PEDF来抑制内皮管状结构的形成。这些发现揭示了这种人参皂苷作用的新机制,可能在抗癌和抗血管生成治疗中具有价值。